Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Working Capital Changes: 2017-2024

Historic Other Working Capital Changes for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $21.9 million.

  • BridgeBio Pharma's Other Working Capital Changes fell 214.15% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.8 million, marking a year-over-year decrease of 3.95%. This contributed to the annual value of $21.9 million for FY2024, which is 502.26% up from last year.
  • As of FY2024, BridgeBio Pharma's Other Working Capital Changes stood at $21.9 million, which was up 502.26% from -$5.4 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Other Working Capital Changes registered a high of $21.9 million during FY2024, and its lowest value of -$5.4 million during FY2023.
  • Its 3-year average for Other Working Capital Changes is $10.6 million, with a median of $15.3 million in 2022.
  • In the last 5 years, BridgeBio Pharma's Other Working Capital Changes tumbled by 135.63% in 2023 and then skyrocketed by 502.26% in 2024.
  • BridgeBio Pharma's Other Working Capital Changes (Yearly) stood at $7.1 million in 2020, then surged by 39.06% to $9.8 million in 2021, then spiked by 55.48% to $15.3 million in 2022, then slumped by 135.63% to -$5.4 million in 2023, then skyrocketed by 502.26% to $21.9 million in 2024.